However, for persistent ITP (≥ 3–12 months) in adults, both the ICR and ASH 2019 guidelines state that TPO-RAs can be used as second-line treatment in patients who are corticosteroid-dependent or unresponsive to corticosteroids [12, 13]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.